Mirum Pharmaceuticals (MIRM) Non-Current Assets (2019 - 2026)

Mirum Pharmaceuticals' Non-Current Assets history runs 8 years deep, the most recent figure standing at $321.5 million for Q1 2026.

• On a quarterly basis, Non-Current Assets rose 15.05% year-over-year to $321.5 million in Q1 2026; TTM through Mar 2026 was $1.1 billion, a 0.88% increase from a year earlier, with the FY2025 full-year figure at $293.1 million, up 5.45% from the prior year.
• Non-Current Assets grew to $321.5 million in Q1 2026 per MIRM's latest filing, from $293.1 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $321.5 million in Q1 2026 and bottomed at $60.1 million in Q2 2023.
• The 5-year median for Non-Current Assets is $262.1 million (2023), against an average of $227.2 million.
• Across the five-year window, Non-Current Assets surged 2639.19% in 2022 and slumped 59.95% in 2023, its largest moves.
• Year by year, Non-Current Assets stood at $162.7 million in 2022, then surged by 59.26% to $259.1 million in 2023, then grew by 7.29% to $278.0 million in 2024, then grew by 5.45% to $293.1 million in 2025, then grew by 9.67% to $321.5 million in 2026.
• Per Business Quant, the three latest MIRM Non-Current Assets figures stand at $321.5 million (Q1 2026), $293.1 million (Q4 2025), and $254.5 million (Q3 2025).